During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell ...

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...

A hidden “jack-in-the-box” mechanism inside T cells may hold the key to unlocking more powerful cancer immunotherapies.

Summary • Pfizer’s stock is up 1.8% to $26.305 during intraday trading, driven by recent collaborative agreements.• Agreements with Adaptive Biotechnologies focus on T-cell receptor discovery and data ...

As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizable potential payout down the line. | Seattle’s Adaptive Biotechnologies ...

AstraZeneca plc (Nasdaq: AZN) is sharply expanding its ambitions in hematology and cell therapy, unveiling new clinical data ...

Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...

A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...

By manipulating this pathway, scientists may be able to tweak the immune response to treat cancers, autoimmune disorders, and more.

Erythropoietin, the protein that drives red blood cell formation, also induces tolerance in dendritic cells, leading to the ...

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...